Io Biotech, a company listed on the NASDAQ as IOBT, has adopted a new set of amended and restated bylaws.

IO Biotech, Inc. has announced changes to its bylaws in a recent 8-K filing with the Securities and Exchange Commission. The amended and restated bylaws, effective immediately, introduce several key amendments and updates. The changes include revisions to procedural mechanics and disclosure requirements for stockholder nominations, proposal submissions, and director eligibility. The bylaws also address matters related to Rule 14a-19 under the Exchange Act, update procedures for stockholder meetings, and ensure compliance with recent changes to the Delaware General Corporation Law. The full text of the document is available as Exhibit 3.1 to the Current Report on Form 8-K. The filing was signed by Mai-Britt Zocca, Ph.D., Chief Executive Officer of IO Biotech, and is a testament to the company’s commitment to transparent governance practices and adherence to regulatory standards. IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on the T-win technology platform.